Shelton Capital Management Supernus Pharmaceuticals, Inc. Transaction History

Shelton Capital Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 31, 2019	SELL	$30.84 - $49.51 $160,275 - $257,303	-5,197 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $8,155 - $10,801	191 Added 3.82%	5,197 $262,000
Q2 2018 Aug 10, 2018	BUY	$44.1 - $59.85 $21,035 - $28,548	477 Added 10.53%	5,006 $300,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $168,252 - $212,410	4,529 New	4,529 $207,000
Q3 2017 Nov 14, 2017	SELL	$36.75 - $49.65 $182,978 - $247,207	-4,979 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	4,979	4,979 $215,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

Stay updated on Shelton Capital Management with notifications on news.